Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Ubenimex (Primary)
- Indications Lymphoedema
- Focus Therapeutic Use
- Acronyms ULTRA
- Sponsors Eiger BioPharmaceuticals
- 31 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
- 31 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Sep 2018.
- 04 Jan 2018 According to an Eiger BioPharmaceuticals media release, enrollment in this trial has been completed and results are expected in second half of 2018.